Literature DB >> 5673215

Lethal complications of the Ehlers-Danlos syndrome.

P Beighton.   

Abstract

Death from arterial bleeding or gastrointestinal perforation has previously been reported in more than 15 patients with the Ehlers-Danlos syndrome. On a basis of 100 personally examined patients and a review of published accounts, these events seem particularly likely to occur in two distinct and recognizable forms (the gravis and the ecchymotic forms) of the syndrome.

Entities:  

Mesh:

Year:  1968        PMID: 5673215      PMCID: PMC1986531          DOI: 10.1136/bmj.3.5619.656

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  16 in total

1.  The structure of the connective tissue, an explanation of the symptoms of the Ehlers-Danlos syndrome.

Authors:  L H JANSEN
Journal:  Dermatologica       Date:  1955-02

2.  The Ehlers-Danlos syndrome and multiple neurofibromatosis in a kindred of mixed derivation, with special emphasis on hemostasis in the Ehlers-Danlos syndrome.

Authors:  R M GOODMAN; J M LEVITSKY; I A FRIEDMAN
Journal:  Am J Med       Date:  1962-06       Impact factor: 4.965

3.  Ehlers-Danlos syndrome; report of a case with onset at age 29.

Authors:  P H JACOBS
Journal:  AMA Arch Derm       Date:  1957-10

4.  Surgical significance of the Ehlers-Danlos syndrome.

Authors:  F J Rybka; E T O'Hara
Journal:  Am J Surg       Date:  1967-03       Impact factor: 2.565

5.  [Visceral and hemorrhagic consequences of Ehlers-Danlos disease].

Authors:  R André; G Duhamel; D Vergoz; R Lavallée
Journal:  Bull Mem Soc Med Hop Paris       Date:  1965-06-11

6.  Ehlers-Danlos syndrome causing intestinal perforation.

Authors:  R T Aldridge
Journal:  Br J Surg       Date:  1967-01       Impact factor: 6.939

7.  Spontaneous carotid-cavernous fistula. Ehlers-Danlos syndrome and related conditions.

Authors:  C J Graf
Journal:  Arch Neurol       Date:  1965-12

8.  Heterogeneity of the Ehlers-Danlos syndrome: description of three clinical types and a hypothesis to explain the basic defect(s).

Authors:  A P Barabas
Journal:  Br Med J       Date:  1967-06-03

9.  Ehlers-Danlos syndrome and "congenital" arteriovenous fistulae. A clinicopathologic study of a family.

Authors:  H T Lynch; A L Larsen; R Wilson; C L Magnuson
Journal:  JAMA       Date:  1965-11-29       Impact factor: 56.272

10.  Ehlers-Danlos syndrome.

Authors:  R M Bannerman; C J Graf; J F Upson
Journal:  Br Med J       Date:  1967-08-26
View more
  9 in total

1.  Spontaneous rupture of the abdominal aorta.

Authors:  T G Williams
Journal:  Postgrad Med J       Date:  1977-04       Impact factor: 2.401

Review 2.  The skin in genetically-controlled metabolic disorders.

Authors:  P C Newbold
Journal:  J Med Genet       Date:  1973-06       Impact factor: 6.318

3.  Gastrointestinal complications of the Ehlers-Danlos syndrome.

Authors:  P H Beighton; J L Murdoch; T Votteler
Journal:  Gut       Date:  1969-12       Impact factor: 23.059

4.  Ehlers-Danlos syndrome (two cases).

Authors:  P Beighton
Journal:  Proc R Soc Med       Date:  1968-10

5.  Ehlers-Danlos syndrome with vertebral artery aneurysm.

Authors:  A P Barabas
Journal:  Proc R Soc Med       Date:  1969-07-07

6.  Two cases of Ehlers-Danlos syndrome with gastrointestinal complications.

Authors:  A Hayakawa; K Fujimoto; H Ibayashi
Journal:  Gastroenterol Jpn       Date:  1982

Review 7.  Ehlers-Danlos syndrome complicated by eventration of the diaphragm, colonic perforation and jejunal perforation--a case report.

Authors:  T Iwama; H Sato; T Matsuzaki; S Mitaka; K Deguchi; Y Mishima
Journal:  Jpn J Surg       Date:  1989-05

8.  Abnormalities of the lungs and thoracic cage in the Ehlers-Danlos syndrome.

Authors:  J G Ayres; F M Pope; J F Reidy; T J Clark
Journal:  Thorax       Date:  1985-04       Impact factor: 9.139

9.  Isolation, characterisation, and genome sequencing of Rhodococcus equi: a novel strain producing chitin deacetylase.

Authors:  Qinyuan Ma; Xiuzhen Gao; Xinyu Bi; Linna Tu; Menglei Xia; Yanbing Shen; Min Wang
Journal:  Sci Rep       Date:  2020-03-09       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.